FDA Restricts Use Of Liver Drug Ocaliva Due To Risk Of Liver Failure
SILVER SPRING, Md. — The Food and Drug Administration on May 26 said it is restricting the use of the liver disease drug Ocaliva in patients who have primary biliary cholangitis...To view the full article, register now.
Already a subscriber? Click here to view full article